| Name | Title | Contact Details |
|---|
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
Psyadon Pharmaceuticals is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.
Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hanford Pharmaceuticals is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.